Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Abstract Background The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. Simi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-05-01
Col·lecció:	Journal of Experimental & Clinical Cancer Research
Matèries:	Non-Small Cell Lung Cancer Osimertinib Resistance Epidermal Growth Factor Receptor Pemetrexed Cisplatin
Accés en línia:	http://link.springer.com/article/10.1186/s13046-019-1240-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!